Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Sagimet announces positive results for Ascletis’ denifanstat in moderate to severe acne

Over 50 million people across the US live with acne, a condition with no cure that often requires chronic treatment

- PMLiVE

ASH 2025: where Magic Kingdom met the spirit of Andor

At ASH 2025, bold science and immersive experience bumped shoulders with a clear call to fight for patients

- PMLiVE

Why Sleep Health is the Missing Link in Women’s Wellness

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with...

Medscape Education

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

McNamara’s Fallacy

Why marketing science is harder than you think

Photo of Tim Wright plus title of talk

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Alzheimer’s disease – the future of diagnosis and treatment in Europe

Recognising symptoms early and acting quickly can make a real difference to the lives of patients

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Skyhawk Therapeutics’ SKY-0515 shows positive results in Huntington’s disease

Huntington’s disease affects over 40,000 patients in the US and hundreds of thousands globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links